Philips Respironics Announces Major Device Recall

On June 14, 2021, Royal Philips announced a voluntary recall notification in the United States and a field safety notice internationally for certain sleep apnea and respiratory care devices manufactured by its subsidiary, Philips Respironics. The action involved specific continuous positive airway pressure (CPAP) machines, bilevel positive airway pressure (BiPAP) devices, and mechanical ventilators, including models from the first-generation DreamStation product family. The recall addressed potential health risks associated with polyester-based polyurethane (PE-PUR) sound-abatement foam used to reduce noise and vibration inside the devices. Testing indicated that the foam could deteriorate into particles or release certain chemicals into the airflow, potentially exposing users through inhalation or ingestion. Philips initiated the recall to notify patients and healthcare providers, provide safety guidance, and establish a repair and replacement program for affected equipment. The June 2021 recall became a major milestone in Philips' healthcare technology history, prompting an extensive international effort to evaluate device safety, support patients, and improve product quality. The action affected millions of sleep therapy and respiratory care devices worldwide, making close cooperation with medical professionals, regulatory agencies, and healthcare organizations essential. Philips expanded its repair and replacement operations, conducted additional laboratory testing, and worked with independent specialists to investigate the potential risks associated with foam degradation and chemical emissions. The U.S. Food and Drug Administration continued monitoring the recall and providing recommendations for affected patients and healthcare providers. The event reinforced the importance of rigorous medical device testing, transparent safety communication, regulatory oversight, and ongoing quality improvement. It also became an important part of Philips' broader efforts to strengthen patient safety and confidence in its healthcare technologies.